TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01653301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELAC RT
Description: Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX RT
Description: * Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;~* Oxaliplatin: 130mg/m2, days 1, 19, 38~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost).
Study: NCT01480362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: Used therapy systems:~KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith \& Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Wound Therapy
Description: Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
Study: NCT01596660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaina 0.5%
Description: Bupivacaina 0.5% 20cc
Study: NCT04637724

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: 10 sessions of Anodal tDCS of the dorsolateral prefrontal cortex over a period of 5 consecutive days (two session a day). Each session includes the placement of two tDCS electrodes (anodal at left prefrontal area and cathodal above the vertex) and 20 mins of anodal prefrontal stimulation. The tDCS session is received two time a day with a 3-5 hours interveal betwen sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: 10 sessions of Anodal tDCS of the dorsolateral prefrontal cortex over a period of 5 consecutive days (two session a day). Each session includes the placement of two tDCS electrodes (anodal at left prefrontal area and cathodal above the vertex) and 20 mins of anodal prefrontal stimulation. The tDCS session is received two time a day with a 3-5 hours interveal betwen sessions.
Study: NCT03540589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy specific vibration device
Description: It is a device that produces vibration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy specific vibration device
Description: It is a device that produces vibration

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction
Description: The distraction will be obtained through tablet with videos

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction
Description: The distraction will be obtained through tablet with videos
Study: NCT04252313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Studies have been conducted to assess the effects of sound and noise on neonatal stress. Recently, music is being used in neonatal units to improve physiological and behavioral outcomes (Harling et al, 2009). Of the few studies done on the effectiveness of music during circumcision is a randomized double-blinded controlled trial conducted by Joyce et al (2001): it found that some physiologic outcomes were significantly lower among the music group in comparison to the EMLA group. They concluded that there is preliminary evidence to support the efficacy of EMLA and music in pain management of newborn circumcision; however, more rigorous studies are warranted for conclusive results.
Study: NCT01031316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nondisclosure of screening echocardiogram results
Description: Subjects will be randomized to nondisclosure of screening echocardiogram results.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Disclosure of screening echocardiogram results
Description: Subjects will be randomized to disclosure of screening echocardiogram results.
Study: NCT04075890

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a non-invasive brain stimulation method by which constant low direct current can be delivered to the sculpt for changing the excitability of neuronal structure adjunct to the stimulating electrode.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a non-invasive brain stimulation method by which constant low direct current can be delivered to the sculpt for changing the excitability of neuronal structure adjunct to the stimulating electrode.
Study: NCT03957421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aquatic exercise, land based exercise
Description: general warm up and cool down. general exercises and treadmill training at self-selected intensity.
Study: NCT01596660

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: 20 cc of saline solution 0.9%, to infiltrate each side.
Study: NCT03112330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plasma rich platelet injection
Description: Plasma rich platelet injection with 26-gauge needle and 2cc syringe on inferior turbinate mucosa

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saline nasal spray
Description: two puffs of isotonic saline nasal spray twice daily
Study: NCT01054404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Furosemide 0.3 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (up to 5mL)
Study: NCT03929991

Intervention type: OTHER
Intervention: Observational
Description: To record social and clinical characteristics

Intervention type: OTHER
Intervention: Observational
Description: To record social and clinical characteristics
Study: NCT02547090

Intervention type: PROCEDURE
Intervention: The use of two attending surgeons during posterior spinal fusion
Description: Patients in the experimental group received posterior spinal fusion with two attending surgeons. Patients in the control group received posterior spinal fusion with one attending surgeon and one first assist, which could be a resident, PA, or nurse.
Study: NCT01499459

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: autologous mesenchymal stem cell transplantation
Description: Every patient is given 1x106 MSCs per kg infused via peripheral vein.
Study: NCT02148575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management Group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Management Group
Study: NCT00556478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PSD502, contains a mixture of lidocaine and prilocaine
Description: PSD502 spray contains a mixture of lidocaine and prilocaine with Norflurane (HFA-134a) is used as both propellant and solvent. A single dose consists of 3 sprays applied to the glans penis.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PSD502, contains a mixture of lidocaine and prilocaine
Description: PSD502 spray contains a mixture of lidocaine and prilocaine with Norflurane (HFA-134a) is used as both propellant and solvent. A single dose consists of 3 sprays applied to the glans penis.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a metered dose aerosol spray that is identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing.~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period.
Study: NCT01974843

Intervention type: DRUG
Intervention: Levobupivacaine
Description: in the levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg levobupivacaine plus 35 mg tramadol), resulting in a total volume of 1 ml/kg at maximum volume of 15 ml

Intervention type: DRUG
Intervention: Bupivacaine
Description: in the bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg bupivacaine plus 35 mg tramadol)
Study: NCT06796010

Intervention type: OTHER
Intervention: Visible Light Exposure - Treated zones
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

Intervention type: OTHER
Intervention: Visible Light Exposure - Treated zones
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

Intervention type: OTHER
Intervention: Visible Light Exposure - Treated zones
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

Intervention type: OTHER
Intervention: Visible Light Exposure - Treated zones
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

Intervention type: OTHER
Intervention: Visible Light Exposure - Untreated zone
Description: The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
Study: NCT03657134

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CoVa-2 Monitoring System
Description: Upon completion of EP procedure, CoVa-2 monitoring system will be applied until discharge. Data from the sensor will be sent to the Gateway and Cloud-based system and analyzed retrospectively.
Study: NCT02993822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orvepitant Maleate
Description: Tablet, once daily, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orvepitant Maleate
Description: Tablet, once daily, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orvepitant Maleate
Description: Tablet, once daily, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, once daily, oral
Study: NCT02565264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plasma-derived exosomes
Description: Plasma samples from the participants will be filtered through 0.45 μm and 0.20 μm filters. The samples will be filtered through 0.02 μm filter to trap exosomes with the filter. Saline solution will be loaded from the other side of the 0.02 μm filter to obtain exosome rich buffer. The plasma-derived exosomes will be applied to the participants' ulcers daily for 28 days.
Study: NCT00670618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPP-ACP (GC Tooth Mousse)
Description: Calcium and phosphate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPP-ACP (GC MI Paste Plus)
Description: Calcium, phosphate and fluoride

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride (Elmex Medical Gel)
Description: Fluoride
Study: NCT02700035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bii-Zin-Da-De-Dah (Listening to One Another)
Description: Bii-Zin-Da-De-Dah (Listening to One Another) is a family-centered alcohol and drug prevention program for Anishinabe communities. It was the first American Indian adaptation of the Iowa Strengthening Families Program (now called the Strengthening Families Program). This program has been developed and adapted in partnership with multiple Anishinabe communities over a span of 13 years. Bii-Zin-Da-De-Dah has been enormously popular in communities. It is currently the center piece of a National Canadian Mental Health Promotion Program funded by the Public Health Agency of Canada. Now in its third Phase, focusing on national scale-up among first nations people, it has been adapted for eight cultures and translated into French in a recent implementation in Canada.
Study: NCT03122808

Intervention type: DIAGNOSTIC_TEST
Intervention: Uterine Activity Analysis
Description: Analysis of components of uterine activity; contraction rate, length of contraction, length of relaxation and other values based off these measurements.

Intervention type: DIAGNOSTIC_TEST
Intervention: Uterine Activity Analysis
Description: Analysis of components of uterine activity; contraction rate, length of contraction, length of relaxation and other values based off these measurements.

Intervention type: DIAGNOSTIC_TEST
Intervention: Partogram Analysis
Description: Analysis of slope of partogram

Intervention type: DIAGNOSTIC_TEST
Intervention: Partogram Analysis
Description: Analysis of slope of partogram
Study: NCT02337998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: load carriage
Study: NCT04223765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR.k.28
Description: Three dose levels will be evaluated: Dose level 1 (5x10\^5 cells/kg), Dose level 2 (1x10\^6), and dose level 3 (2x10\^6 cells/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2/day IV for 3 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2/day IV for 3 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 70 mg/m\^2/day administered over 3 consecutive days.
Study: NCT02047773

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Duration
Description: If bacterial load checked on day 7 is less than 10\^6 cfu/ml then antibiotics will be stopped on day 8 (results take 24hrs). If bacterial load remains higher than this then patients will continue on intravenous antibiotics. Bacterial load will be checked again on day 10. If bacterial load is less than 10\^6 cfu/ml then antibiotics will be stopped on day 11. If bacterial load remains higher than this then the patient will complete a 14day course of antibiotics. All patients will be seen and bacterial load assessed on day 1, day 7, day 10, day 14 and day 21.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colomycin
Description: If there is a clinical deterioration a second antibiotic to augment treatment (Colomycin) will be added for both arms of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colomycin
Description: If there is a clinical deterioration a second antibiotic to augment treatment (Colomycin) will be added for both arms of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Study: NCT01369472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilatrend SR capsule
Description: single oral administration in period 1 or 2, 3 for each sequential group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilatrend SR capsule
Description: single oral administration in period 1 or 2, 3 for each sequential group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilatrend SR capsule
Description: single oral administration in period 1 or 2, 3 for each sequential group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilatrend SR capsule
Description: single oral administration in period 1 or 2, 3 for each sequential group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilatrend SR capsule
Description: single oral administration in period 1 or 2, 3 for each sequential group.
Study: NCT03874741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT200
Description: Anti-EGFR monoclonal antibody DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression~Other Names:~• SCT200
Study: NCT02105558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Description: ￼An epidural involves injecting pain-blocking medication into a space between the vertebrae and the spinal fluid; it usually takes about 15 minutes to work.~Epidurals will be placed in a sterile fashion using a 17g Tuohy needle to locate the epidural space via loss-of-resistance to saline at the lumbar vertebral level. 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine will then be used for test dose to exclude intrathecal or intravenous placement of the catheter. Epidural solution composed of 5ml of 0.2% ropivacaine and another 5 ml of 0.2% ropivacaine will then be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined spinal and epidural anesthesia
Description: A spinal is an injection directly into the spinal fluid; it is given in addition to the epidural technique and takes effect in five minutes.~The epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr.
Study: NCT03083652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Neuromuscular electrical stimulation (30 minutes per day, 5 days/week) of the quadriceps femoris and gluteus maximus

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Conventional physiotherapy with NMES device NOT activated
Study: NCT02594670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DU20 and HT7 combination
Description: acupoints combination includes Baihui (DU20) and Shenmen(HT7),which was considered as the optimal clinical efficay among various combinations of acupoints.

Intervention type: OTHER
Group type: OTHER
Intervention: DU20 and SP6 combination
Description: acupoints combination of Baihui (DU20) and Sanyinjiao (SP6), which should have some clinical efficay among various combinations of acupoints.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: DU20 and SA combination
Description: Combination of Baihui (DU20) and a Sham acupoint (SA), which should have least clinical efficacy among these three types of acupoints combinations.
Study: NCT02677207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
Study: NCT02643563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Description: Ropivacaine 0.5% is used for low-volume ultrasound-guided interscalene brachial plexus block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 1%
Description: Ropivicaine 1% is used for low-volume ultrasound-guided interscalene brachial plexus block.
Study: NCT04381598

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A placebo without the active drug will be placed in the control sites.
Study: NCT05367648

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elio
Description: Elio™ supplementation, a protein hydrolysate derived from fava bean protein extract
Study: NCT02643563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5% + epinephrine 1:200,000
Description: Bupivacaine 0.5% + epinephrine 1:200,000 is used for low-volume ultrasound-guided interscalene brachial plexus block.
Study: NCT04463186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Static Stretching
Description: Static stretching for 2 minutes (SS2), static stretching for 4 minutes (SS4), and static stretching for 8 minutes (SS8). Each static stretching (SS) trial involved varied repetitions of 30-seconds self-stretches and 20-seconds relax periods.
Study: NCT00516373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KU-0059436 (AZD2281)(PARP inhibitor)
Description: oral
Study: NCT01917981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personal Heart Rhythm Monitor
Study: NCT00384930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 2.5 mg tadalafil tablet by mouth once a day for twelve weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 5 mg tadalafil tablet by mouth once a day for twelve weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 10 mg tadalafil tablet by mouth once a day for twelve weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20 mg tadalafil tablet by mouth once a day for twelve weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet taken by mouth one a day for twelve weeks